Resistance mutation info of drug
| Drug General Information | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug ID | D03UVS | ||||||||||
| Drug Name | Gemcitabine | Drug Info | |||||||||
| Synonyms | DDFC; DFdC; DFdCyd; Folfugem; GEO; Gamcitabine; GemLip; Gemcel; Gemcin; Gemcitabina; Gemcitabinum; Gemtro; Gemzar; Zefei; Gemcitabine HCl; Gemcitabine stereoisomer; LY 188011; LY188011; Gemcitabina [INN-Spanish]; Gemcitabinum [INN-Latin]; Gemzar (TN); Gemzar (hydrochloride); Inno-D07001; LY-188011; Gemcitabine (USAN/INN); Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine; 2',2'-DiF-dC; 2',2'-Difluoro-2'-deoxycytidine; 2',2'-Difluorodeoxycytidine; 2'-Deoxy-.beta.-D-2',2'-difluorocytidine; 2'-Deoxy-2',2'-difluorocytidine; 4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; 4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one; 4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one | ||||||||||
| Drug Type | Small molecular drug | ||||||||||
| Therapeutic Class | Anticancer Agents | ||||||||||
| Company | Eli Lilly | ||||||||||
| Structure |
|
||||||||||
| Drug Resistance Mutations | |||||||||||
| Target Name | Deoxycytidine kinase (DCK) | Target Info | |||||||||
| Gene Name | DCK | ||||||||||
| Uniprot ID | DCK_HUMAN | ||||||||||
| Species | Homo sapiens | ||||||||||
| Reference Sequence | MATPPKRSCPSFSASSEGTRIKKISIEGNIAAGKSTFVNILKQLCEDWEVVPEPVARWCN VQSTQDEFEELTMSQKNGGNVLQMMYEKPERWSFTFQTYACLSRIRAQLASLNGKLKDAE KPVLFFERSVYSDRYIFASNLYESECMNETEWTIYQDWHDWMNNQFGQSLELDGIIYLQA TPETCLHRIYLRGRNEEQGIPLEYLEKLHYKHESWLLHRTLKTNFDYLQEVPILTLDVNE DFKDKYESLVEKVKEFLSTL [Homo sapiens] |
||||||||||
| Targeted Disease | Gastric cancer | ||||||||||
| Drug Resistance Mutations |
|
||||||||||
| References | |||||||||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.